Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oli...
Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...
Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has publis...
DDL, a leading provider of package, product, and material testing services, is pleased to announce the opening of a new Good Manufacturing Practice (GMP) l...
Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Rec...
Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...
Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute ...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced pharmacokinetic a...
Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that the U.S. Food and D...
Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
GSK plc announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the inve...
Nxera Pharma Co., Ltd. announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGlu...
© 2025 Biopharma Boardroom. All Rights Reserved.
